Progression-free or overall survival…revisited in BOLERO-2

CC BY-NC-ND 4.0 · Indian J Med Paediatr Oncol 2014; 35(01): 1-2
DOI: 10.4103/0971-5851.133701

EDITORIAL

Sudeep Gupta

Editor-in-Chief, Tata Memorial Centre, Mumbai, Maharashtra, India

References
1 Gupta S. Progression-free or overall… That is the question….Indian J Med Paediatr Oncol 2010;31:103-4.
2 Baselga J, Campone M, Piccart M, Burris HA 3 rd , Rugo HS, Sahmoud T, et al. Everolimus in postmenopausal hormone-receptor-positive advanced breast cancer. N Engl J Med 2012;366:520-9.
3 Burris HA 3 rd , Lebrun F, Rugo HS, Beck JT, Piccart M, Neven P, et al. Health-related quality of life of patients with advanced breast cancer treated with everolimus plus exemestane versus placebo plus exemestane in the phase 3, randomized, controlled, BOLERO-2 trial. Cancer 2013;119:1908-15.
4 Piccart M, Hortobagyi GN, Campone M, Pritchard KI, Noguchi S, Rugo H, et al. Everolimus Plus Exemestane for Hormone Receptor-Positive (HR+), Human Epidermal Growth Factor Receptor-2-Negative (HER2-) Advanced Breast Cancer (BC): Overall Survival Results From BOLERO-2. Presented at EBCC-9; 19-21 March 2014; Glasgow, Scotland. Abstract 1 LBA.
5 Hortobagyi GN, Piccart-Gebhart MJ, Rugo HS, Burris HA, Campone M, Noguchi S, et al. Correlation of molecular alterations with efficacy of everolimus in hormone receptor-positive, HER2-negative advanced breast cancer: Results from BOLERO-2. 2013 ASCO Annual Meeting. Abstract LBA509.